Cited 17 times in
Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김도영 | - |
dc.contributor.author | 김범경 | - |
dc.contributor.author | 김승업 | - |
dc.contributor.author | 박준용 | - |
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 정규식 | - |
dc.contributor.author | 한광협 | - |
dc.date.accessioned | 2017-11-02T08:18:08Z | - |
dc.date.available | 2017-11-02T08:18:08Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 1352-0504 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/154314 | - |
dc.description.abstract | We compared the viral suppressive efficacy of tenofovir disoproxil fumarate (TDF) mono-rescue therapy (TDF group) and TDF plus entecavir (ETV) combination-rescue therapy (TDF + ETV group) in chronic hepatitis B (CHB) patients with lamivudine resistance and entecavir resistance. One hundred and thirty-three CHB patients with lamivudine and entecavir resistance were investigated. Ninety-six patients were treated with TDF and 37 with TDF + ETV for at least 6 months. We compared the virologic response rate (HBV DNA level <20 IU/mL) between the two groups and identified the predictive factors of treatment outcome. There were no significant differences between the two groups in demographic characteristics. Up to 24 months [median: 18 (range 6-24) months], 85.4% and 89.2% of the TDF group and TDF + ETV group, respectively, achieved a virologic response (P=.068). Only the HBV DNA level at baseline was significantly associated with a virologic response in the multivariate analysis. In a subanalysis of patients with HBV DNA levels ≥4 log (IU/mL) at baseline, a higher proportion of patients in the TDF + ETV group than the TDF group achieved a virologic response (92.9% vs 68.3%; P<.001), while 90% of patients with HBV DNA (IU/mL) levels <4 log in all both TDF and TDF + ETV groups achieved a virologic response. TDF mono-rescue therapy is a reasonable option in patients with lamivudine resistance and entecavir resistance. However, the combination strategy should be considered in patients with high baseline HBV DNA levels. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Blackwell Scientific Publications | - |
dc.relation.isPartOf | JOURNAL OF VIRAL HEPATITIS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Antiviral Agents/pharmacology | - |
dc.subject.MESH | Antiviral Agents/therapeutic use* | - |
dc.subject.MESH | DNA, Viral/blood | - |
dc.subject.MESH | Drug Resistance, Viral* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Guanine/analogs & derivatives* | - |
dc.subject.MESH | Guanine/pharmacology | - |
dc.subject.MESH | Guanine/therapeutic use | - |
dc.subject.MESH | Hepatitis B virus/drug effects* | - |
dc.subject.MESH | Hepatitis B virus/isolation & purification | - |
dc.subject.MESH | Hepatitis B, Chronic/drug therapy* | - |
dc.subject.MESH | Hepatitis B, Chronic/virology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lamivudine/pharmacology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Tenofovir/pharmacology | - |
dc.subject.MESH | Tenofovir/therapeutic use* | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Viral Load | - |
dc.subject.MESH | Young Adult | - |
dc.title | Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance | - |
dc.type | Article | - |
dc.publisher.location | England | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | S. Lee | - |
dc.contributor.googleauthor | S. H. Ahn | - |
dc.contributor.googleauthor | K. S. Jung | - |
dc.contributor.googleauthor | D. Y. Kim | - |
dc.contributor.googleauthor | B. K. Kim | - |
dc.contributor.googleauthor | S. U. Kim | - |
dc.contributor.googleauthor | O. Baatarkhuu | - |
dc.contributor.googleauthor | H. J. Ku | - |
dc.contributor.googleauthor | K. Han | - |
dc.contributor.googleauthor | J. Y. Park | - |
dc.identifier.doi | 10.1111/jvh.12623 | - |
dc.contributor.localId | A00487 | - |
dc.contributor.localId | A00654 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A03578 | - |
dc.contributor.localId | A04268 | - |
dc.contributor.localId | A00385 | - |
dc.relation.journalcode | J01928 | - |
dc.identifier.eissn | 1365-2893 | - |
dc.identifier.pmid | 27766731 | - |
dc.identifier.url | http://onlinelibrary.wiley.com/doi/10.1111/jvh.12623/abstract | - |
dc.subject.keyword | chronic hepatitis B | - |
dc.subject.keyword | entecavir | - |
dc.subject.keyword | multidrug resistance | - |
dc.subject.keyword | tenofovir | - |
dc.subject.keyword | virologic response | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.alternativeName | Kim, Beom Kyung | - |
dc.contributor.alternativeName | Kim, Seung Up | - |
dc.contributor.alternativeName | Park, Jun Yong | - |
dc.contributor.alternativeName | Ahn, Sang Hoon | - |
dc.contributor.alternativeName | Jung, Kyu Sik | - |
dc.contributor.alternativeName | Han, Kwang Hyup | - |
dc.contributor.affiliatedAuthor | Kim, Beom Kyung | - |
dc.contributor.affiliatedAuthor | Kim, Seung Up | - |
dc.contributor.affiliatedAuthor | Park, Jun Yong | - |
dc.contributor.affiliatedAuthor | Ahn, Sang Hoon | - |
dc.contributor.affiliatedAuthor | Jung, Kyu Sik | - |
dc.contributor.affiliatedAuthor | Han, Kwang Hyup | - |
dc.contributor.affiliatedAuthor | Kim, Do Young | - |
dc.citation.title | Journal of Viral Hepatitis | - |
dc.citation.volume | 24 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 141 | - |
dc.citation.endPage | 147 | - |
dc.identifier.bibliographicCitation | JOURNAL OF VIRAL HEPATITIS, Vol.24(2) : 141-147, 2017 | - |
dc.date.modified | 2017-11-01 | - |
dc.identifier.rimsid | 42286 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.